|Living with Adult ADHD||ADHD in Women||Apps & Tools|
|Signs & Symptoms||Health & Sleep||Time Management|
|First 100 Days||ADHD at Work||Relationships|
|ADHD Parenting Home||Parenting Strategies||ADHD Teens|
|Oppositional Defiant||Health & Nutrition||Social Skills|
|Discipline Fixes||Sleep||Organization Skills|
|ADHD Treatment Home||Natural Treatments||Treating Kids|
|Medications||Diet & Nutrition||Treating Kids Naturally|
|Medication Reviews||Side Effects||First 100 Days|
|Learning Home||Homework Help||Learning Disabilities|
|School Accommodations||Organization Skills||Teachers' Guide|
|IEP/504 Plan||Behavior at School||High School|
|ADHD Symptoms Home||Self-Tests||ADHD in Women|
|ADHD Symptoms||Related Conditions||Diagnosing Kids|
|Types of ADHD||Diagnosing ADD||Dealing with Diagnosis|
|Give a Gift|
Noven Receives FDA Warning Letter for Daytrana Patch
The FDA issued a warning letter for the Daytrana patch pertaining to consumers' problems in removing the release liner, but not the safety of medication.
Friday January 11th - 10:41am
Noven Pharmaceuticals received a warning letter, which stemmed from a July inspection of their production facilities, regarding the Daytrana patch.
The letter, which was released January 10, noted that some patients had difficulty removing the release liner from the Daytrana patch. The letter did not restrict production or shipment of the patch, but asked for further analysis of possible deficiencies in the product and its backing. It also stated that failure to address the issues may lead to regulatory action.
Noven submitted a response to the FDA, and made a statement saying they are working to "fully resolve the issues."